Concourse Financial Group Securities, Inc. Protara Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.67 Billion
Q4 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share
Q4 2024 Feb 13, 2025	BUY	$1.68 - $7.53 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$1.7 - $2.4 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$1.96 - $4.14 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.86 - $4.83 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.12 - $1.93 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.64 - $2.93 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.64 - $2.93 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$2.27 - $3.59 $0 - $0
Q1 2023 May 15, 2023	BUY	$2.76 - $3.91 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$2.43 - $3.7 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$2.96 - $4.27 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$2.8 - $5.33 $0 - $0
Q1 2022 May 09, 2022	BUY	$4.19 - $6.9 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$6.15 - $7.76 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$6.38 - $9.3 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$8.68 - $16.99 $0 - $0
Q1 2021 May 13, 2021	BUY	$13.75 - $23.86 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$16.97 - $25.34 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$16.76 - $31.89 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$22.0 - $60.7 $0 - $0

Others Institutions Holding TARA

# of Institutions

Shares Held

29.8M

Call Options Held

49.5K

Put Options Held

181K

Ra Capital Management, L.P. Boston, MA

3.4M
Shares

$12.6 Million
0.29% of portfolio
Janus Henderson Group PLC London, X0

2.27M
Shares

$8.45 Million
0.01% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

2.25M
Shares

$8.37 Million
0.02% of portfolio
Toronto Dominion Bank Toronto, Ontario, A6

2.09M
Shares

$7.77 Million
0.02% of portfolio
Opaleye Management Inc. Boston, MA

1.83M
Shares

$6.79 Million
1.88% of portfolio

View Full List

About Protara Therapeutics, Inc.

Ticker TARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,267,400
Market Cap $41.9M
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...

More about TARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account